Over-using chemotherapy in the adjuvant setting

Area of Science:

• Oncology
• Clinical Trial Design
• Breast Cancer Research

Background:

• Adjuvant breast oncology faces challenges with overtreatment due to a focus on marginal statistical improvements.
• The principle of

Purpose of the Study:

• To advocate for a shift away from "one treatment fits all" approaches in adjuvant breast oncology.
• To emphasize the need for better understanding of breast cancer biology to guide treatment decisions.
• To critically review current clinical trial designs and promote the selection of precisely defined patient cohorts.

Main Methods:

• Critically reviewing existing adjuvant breast oncology trial designs.
• Analyzing the limitations of the "add on" clinical trial design model.
• Highlighting the necessity of de-escalating treatment when unnecessary.

Main Results:

• Current trial designs may lead to overtreatment and unnecessary toxic effects.
• The "add on" model in trials does not confirm the necessity of standard therapy when a new treatment shows benefit.
• Focusing on population-level average benefits may detract from individualized care.

Conclusions:

• Adjuvant breast oncology must prioritize avoiding unnecessary and ineffective treatments.
• A deeper understanding of breast cancer biology is essential for personalized medicine.
• Refined clinical trial designs and cohort selection are necessary to prevent overtreatment and ensure patient safety.